Sparc-like protein 1 is a new marker of human glioma progression

Journal of Proteome Research

Volumn 11, Issue 10, 2012, Pages 5011-5021

  Turtoi, Andrei ^a   Musmeci, Davide ^a,b   Naccarato, Antonio Giuseppe ^b   Scatena, Cristian ^b   Ortenzi, Valerio ^b   Kiss, Robert ^c   Murtas, Daniela ^d   Patsos, Georgios ^a   Mazzucchelli, Gabriel ^a   De Pauw, Edwin ^a   Bevilacqua, Generoso ^b   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

biomarkers; cancer; glioblastoma; proteomics

Indexed keywords

BIOLOGICAL MARKER; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; OSTEONECTIN; PROTEIN ITB1; PROTEIN TUBA; PROTEOME; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; SPARC LIKE PROTEIN 1; STREPTAVIDIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CANCER GRADING; CANCER GROWTH; CELL COMMUNICATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; UPREGULATION; VALIDATION PROCESS;

ANIMALS; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX PROTEINS; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM GRADING; NEOPLASM TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84867606536     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr3005698     Document Type: Article

References (43)

1. Jessen, K. R. Glial cells Int. J. Biochem. Cell Biol. 2004, 36 (10) 1861-7
2. Nieto-Sampedro, M; Saneto, R. P.; de Vellis, J; Cotman, C. W. The control of glial populations in brain: changes in astrocyte mitogenic and morphogenic factors in response to injury Brain Res. 1985, 343 (2) 320-8
3. Nistér, M; Uhrbom, L; Hesselager, G; Westermark, B. Glial tumors of the CNS. In Glial Cell Development: Basic Principles and Clinical Relevance, 2 nd ed.; Jessen, K. R.;; Richardson, W. D., Eds.; Oxford University Press: Oxford, 2001; pp 437-456.
4. Louis, D. N.; Ohgaki, H; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet., A; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 2007, 114 (2) 97-109
5. Stupp, R; Mason, W. P.; van den Bent, M. J.; Weller, M; Fisher., B; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C; Bogdahn, U; Curschmann, J; Janzer, R. C.; Ludwin, S. K.; Gorlia, T; Allgeier, A; Lacombe, D; Cairncross, J. G.; Eisenhauer, E; Mirimanoff, R. O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma N. Engl. J. Med. 2005, 352 (10) 987-96
6. Iacob, G; Dinca, E. B. Current data and strategy in glioblastoma multiforme J. Med. Life 2009, 2 (4) 386-93
7. Ohgaki, H. Epidemiology of brain tumors Methods Mol. Biol. 2009, 472, 323-42
8. Alves, T. R.; Lima, F. R.; Kahn., S. A.; Lobo, D; Dubois, L. G.; Soletti., R; Borges, H; Neto, V. M. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma Life Sci. 2011, 89 (15-16) 532-9
9. Omuro, A. M.; Faivre, S; Raymond, E. Lessons learned in the development of targeted therapy for malignant gliomas Mol. Cancer Ther. 2007, 6 (7) 1909-19
10. Hegi, M. E.; Diserens, A. C.; Bady, P; Kamoshima, Y; Kouwenhoven, M. C.; Delorenzi, M; Lambiv, W. L.; Hamou, M. F.; Matter, M. S.; Koch, A; Heppner, F. L.; Yonekawa, Y; Merlo, A; Frei, K; Mariani, L; Hofer, S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - a phase II trial Mol. Cancer Ther. 2011, 10 (6) 1102-12
11. Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; Deangelis, L. M.; Abrey, L. E.; Zhang, W. T.; Prados, M. D.; Fine, H. A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) Neuro-Oncol. 2010, 12 (8) 855-61
12. Razis, E; Selviaridis, P; Labropoulos, S; Norris, J. L.; Zhu, M. J.; Song, D. D.; Kalebic, T; Torrens, M.; Kalogera-Fountzila, A; Karkavelas, G; Karanastasi, S; Fletcher, J. A.; Fountzilas, G. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment Clin. Cancer Res. 2010, 15 (19) 6258-66
13. Lu, P; Weaver, V. M.; Werb., Z. The extracellular matrix: a dynamic niche in cancer progression J. Cell Biol. 2012, 196 (4) 395-406
14. Branle, F; Lefranc, F; Camby, I; Jeuken, J; Geurts-Moespot, A; Sprenger, S; Sweep, F; Kiss, R; Salmon, I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Cancer 2002, 95 (3) 641-55
15. Karmakar, S; Banik, N. L.; Patel, S. J; Ray, S. K. Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice Apoptosis 2007, 12 (11) 2077-87
16. Deng, L; Li, G; Li, R; Liu, Q; He, Q; Zhang, J Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo Cancer Biol. Ther. 2010, 9 (11) 875-84
17. De Ridder, L. I.; Laerum., O. D.; Mork., S. J.; Bigner, D. D. Invasiveness of human glioma cell ines in vitro: relation to tumorigenicity in athymic mice Acta Neuropatol. 1987, 72 (3) 207-13
18. Stein, G. H. T98G: an anchorage independent human tumor cell ine that exhibits stationary phase G1 arrest in vitro J. Cell Physiol. 1979, 99 (1) 43-54
19. Castronovo, V; Kischel, P; Guillonneau, F; de Leval, L; Deféchereux, T; De Pauw, E; Neri, D; Waltregny., D. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method Proteomics 2007, 7 (8) 1188-96
20. Conrotto, P; Roesli, C; Rybak, J; Kischel, P; Waltregny, D; Neri, D; Castronovo, V. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis Int. J. Cancer. 2008, 123 (12) 2856-64
21. Belot, N; Rorive, S; Doyen, I; Lefranc, F; Bruyneel, E; De Decker, R; Micik, S; Brotchi, J; Decaestecker, C; Salmon, I; Kiss, R; Camby, I. Molecular characterization of cell-substratum attachments in human glial tumors relates to prognostic features Glia 2001, 36, 375-390
22. Turtoi, A; Musmeci, D; Wang, Y; Dumont, B; Somja, J; Bevilacqua, G; De Pauw, E; Delvenne, P; Castronovo, V. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma J. Proteome Res. 2011, 10 (9) 4302-13
23. Ishihama, Y; Oda, Y; Tabata, T; Sato, T; Nagasu, T; Rappsilber, J; Mann, M. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol. Cell. Proteomics 2008, 4 (9) 1265-1272
24. Pitteri, S. J.; Faca, V. M.; Kelly-Spratt, K. S.; Kasarda, A. E.; Wang, H; Zhang, Q; Newcomb, L; Krasnoselsky, A; Paczesny, S.; Choi, G; Fitzgibbon, M; McIntosh, M. W.; Kemp, C. J.; Hanash, S. M. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells J. Proteome Res. 2008, 7 (4) 1481-9
25. Orazine, C. I.; Hincapie, M.; Hancock, W. S.; Hattersley, M.; Hanke, J. H. A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers J. Proteome Res. 2008, 7 (4) 1542-54
26. Pitteri, S. J.; JeBailey, L.; Faça, V. M.; Thorpe, J. D.; Silva, M. A.; Ireton, R. C.; Horton, M. B.; Wang, H; Pruitt, L. C.; Zhang, Q; Cheng, K. H.; Urban, N; Hanash, S. M.; Dinulescu, D. M. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery PLoS One 2009, 4 (11) e7916
27. Bijian, K.; Mlynarek, A. M.; Balys, R. L.; Jie, S.; Xu, Y.; Hier, M. P.; Black, M. J.; Di Falco, M. R.; LaBoissiere, S.; Alaoui-Jamali, M. A. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment J. Proteome Res. 2009, 8 (5) 2173-85
28. Kuick, R.; Misek, D. E.; Monsma, D. J.; Webb, C. P.; Wang, H.; Peterson, K. J.; Pisano, M.; Omenn, G. S.; Hanash, S. M. Discovery of cancer biomarkers through the use of mouse models Cancer Lett. 2007, 249 (1) 40-8
29. Wu, C. C.; Peng, P. H.; Chang, Y. T.; Huang, Y. S.; Chang, K. P.; Hao, S. P.; Tsang, N. M.; Yeh, C. T.; Chang, Y,S.; Yu, J. S. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation Proteomics 2008, 8 (17) 3605-20
30. Van den Bemd, G. J.; Krijgsveld, J.; Luider, T. M.; van Rijswijk, A. L.; Demmers, J. A.; Jenster, G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice Mol. Cell. Proteomics 2006, 5 (10) 1830-9
31. Claeskens, A; Ongenae, N; Neefs, J. M.; Cheyns, P; Kaijen, P; Cools, M; Kutoh, E. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation Br. J. Cancer. 2000, 82, 1123-1130
32. Safran, M; Chalifa-Caspi, V; Shmueli, O; Olender, T; Lapidot, M; Rosen, N; Shmoish, M; Peter., Y; Glusman, G; Feldmesser, E; Adato, A; Peter, I; Khen, M; Atarot, T; Groner, Y; Lancet, D. Human gene-centric databases at the Weizmann institute of science: GeneCards, UDB, CroW 21 and HORDE Nucleic Acids Res. 2003, 31 (1) 142-6
33. Girard, J. P.; Springer, T. A. Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules J. Biol. Chem. 1996, 271 (8) 4511-7
34. Hambrock, H. O.; Nitsche, D. P.; Hansen, U; Bruckner, P; Paulsson, M; Maurer, P; Hartmann, U. SC1/hevin. An extracellular calcium-modulated protein that binds collagen I J. Biol. Chem. 2003, 278 (13) 11351-8
35. Sullivan, M. M.; Sage, E. H. Hevin/SC1, a matricellular glycoprotein and potential tumor sppressor of the SPARC/BM-40/Osteonectin family Int. J. Biochem. Cell Biol. 2004, 36 (6) 991-6
36. Nelson, P. S.; Plymate, S. R.; Wang, K; True, L. D.; Ware, J. L.; Gan, L; Liu, A. Y.; Hood, L. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma Cancer Res. 1998, 58 (2) 232-6
37. Bendik, I; Schraml, P; Ludwig, C. U. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer Cancer Res. 1998, 58 (4) 626-9
38. Li, P; Qian, J; Yu, G; Chen, Y; Liu, K; Li, J; Wang, J. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer J. Surg. Oncol. 2012, 105 (1) 31-7
39. Esposito, I; Kayed, H; Keleg, S; Giese, T; Sage, E. H.; Schirmacher, P; Friess, H; Kleeff, J. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer Neoplasia 2007, 9 (1) 8-17
40. Zhang, H; Widegren, E; Wang, D. W.; Sun, X. F. SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer Tumour Biol. 2011, 32 (6) 1225-31
41. Lau, C. P.; Poon, R. T.; Cheung, S. T.; Yu, W. C.; Fan, S. T. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma J. Pathol. 2006, 210 (4) 459-68
42. Tai, I. T.; Tang, M. J. SPARC in cancer biology: its role in cancer progression and potential for therapy Drug Resist. Updates 2008, 11 (6) 231-46
43. Bellahcne, A; Castronovo, V. Increased expression of osteonectin and osteopontin, two bonematrix proteins, in human breast cancer Am. J. Pathol. 1995, 146 (1) 95-100